loxo-435
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2022 (NCT05614739)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06641037 | Phase 1 | Oct 31, 2024 | Eli Lilly |
| NCT06644378 | Phase 1 | Oct 31, 2024 | Eli Lilly |
| NCT05614739 | Phase 1 | Dec 31, 2022 | Eli Lilly, Loxo Oncology |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 3 | 3 | 1 | 2022 |
| Loxo Oncology | For profit | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1